Abstract: A photodynamic hyperthermic chemotherapy of cancer comprising topically injecting a photosensitive dye agent, specifically indocyanine green, in the form of an acidic liquid formulation to a tumor or cancer tissue, or a surgically removed site thereof of a patient, and irradiating the tissue or site with light having such an output wavelength that the photosensitive dye agent absorbs the light and generates heat; and an apparatus and a system for photodynamic hyperthermic chemotherapy of cancer comprising a light source and a probe having a light introducing portion capable of topically irradiating a tumor or cancer tissue or a surgically removed site thereof of a patient with light derived from the light source by a continuous wave or a pulse wave at an output wavelength of 600 to 1600 nm and an output of 5000 mW or more.

Abstract: It is intended to provide a primer having a promoter region added thereto; and a method of using the primer having a promoter region added thereto in RNA amplification, gene expression analysis and/or identification analysis of an organism. A primer is constructed by adding a promoter region to a random primer capable of binding to a part highly complementary to an RNA or a primer containing a base sequence complementary to a specific gene. Then, the obtained primer is employed in RNA amplification, gene expression analysis and/or identification analysis of an organism.

Abstract: The present invention provides a human monoclonal antibody that has both activity of inhibiting the aggregation of pathogenic bacteria involved in periodontal diseases and activity of promoting sterilization by leukocytes, that is preferably a monoclonal antibody against 40-kDa OMP, which inhibits the binding of hemin, and that causes no concerns such as side effects. The present invention further provides an agent that acts against periodontal diseases containing the monoclonal antibody. The present invention relates to an antibody binding to 40-kDa OMP or a functional fragment thereof having at least one of (1) activity of inhibiting the coaggregation of P. gingivalis, (2) activity of promoting human neutrophilic phagocytosis, and (3) activity of inhibiting the binding of hemin to 40-kDa OMP.